Fenofibrate for Primary Biliary Cholangitis (PBC)
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in an earlier study of fenofibrate for PBC (clinical trial NCT02823353).
- If you are a woman who can become pregnant, you must use two reliable forms of birth control during the study and for 3 months after the last dose.
- If you are a man with a partner who can become pregnant, you must use barrier contraception, and your partner must use an additional effective birth control method.
- You cannot have stopped fenofibrate treatment before because of side effects.
- You cannot have other active liver diseases besides PBC, or any other medical condition that would make the study unsafe or unclear (like cancer).
- You cannot be pregnant or breastfeeding, and you cannot use long-term immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.